Clinician's Roundtable

Host: Larry Kaskel, MD

Guest: Owen J. Dahl, MBA

What are the greatest challenges in your practice? Is it collections? Or possibly conflicts between your staff? Most likely the greatest challenges don’t have to do with doctoring. Is it time to call in a consultant to help you manage costs effectively and move on? Join host Dr. Larry Kaskel with practice consultant Owen Dahl as they discuss the role of a consultant, the project cycle, and a few tips you and your office manager might use to streamline operations in your practice.

Host: Mark Nolan Hill, MD

Guest: Jawed Fareed, PhD

The FDA has issued an extensive recall on several contaminated heparin products, problems which have been traced back to ingredients from China, which were so similar to heparin that the contaminants fooled standard quality testing. Dr. Jawed Fareed, professor of pathology and pharmacology at Loyola University Chicago Stritch School of Medicine, details the standard quality test process with host Dr. Mark Nolan Hill. How we can prevent future deception with these tests? Further, understanding that the contaminated ingredients came from China, is it fair to ask whether the United States is outsourcing too much of the drug production process?

Host: Mark Nolan Hill, MD

Guest: Jawed Fareed, PhD

The FDA has issued an extensive recall on several contaminated heparin products, problems which have been traced back to ingredients from China. Dr. Jawed Fareed, professor of pathology and pharmacology at Loyola University Chicago Stritch School of Medicine, takes us through the process of heparin production, starting with the initial derivation of the drug from animal tissue. How does the FDA regulate various aspects of the drug production process which occur abroad? Will China tighten up its regulatory process in the wake of the latest heparin anxieties? Dr. Mark Nolan Hill hosts.

Host: Mark Nolan Hill, MD

Guest: Jawed Fareed, PhD

The FDA has issued an extensive recall on several contaminated heparin products, problems which have been traced back to ingredients from China. Dr. Jawed Fareed, professor of pathology and pharmacology at Loyola University Chicago Stritch School of Medicine, has conducted tests on heparin batches since adverse effects from the drug were first reported. He says the issues of heparin contamination are the result of deliberate counterfeiting. If true, what would motivate deliberate acts of counterfeiting? Dr. Mark Nolan Hill hosts.

Host: Mark Nolan Hill, MD

Guest: Jawed Fareed, PhD

The FDA has issued an extensive recall on several contaminated heparin products. What is the contaminant, and what medical problems and risks may be linked to the contaminated heparin? Dr. Jawed Fareed, professor of pathology and pharmacology at Loyola University Chicago Stritch School of Medicine, has conducted tests on heparin batches since adverse effects from the drug were first reported. He shares his expertise on heparin with host Dr. Mark Nolan Hill.

Host: Bill Rutenberg, MD

Guest: Robert Wagner, MD

Whether to admit or observe a ER patient is not always clear cut. What criteria should you use to make this decision? How can you be sure that your decision process will be supported and covered by CMS? What if CMS isn’t ultimately willing to pay for the services? Join host Dr. Bill Rutenberg in conversation with Dr. Robert Wagner, Director and CMO of Accretive Health to discuss the frequent dilemma of whether or not to admit a patient and the tools and guidelines available to support you in that decision.

Host: Bill Rutenberg, MD

Guest: Robert Wagner, MD

Most doctors don’t spend time memorizing Medicare and Medicaid compliance guidelines. Yet, they are often under the gun to make decisions based on reimbursement guidelines. In this segment, Dr. Bill Rutenberg learns about a new program available from Accretive Health called the Sure Decision Clinical Compliance Program where 'on call' doctors versed in CMS guidelines can help attending physicians’ make critical decisions at the point of care. Our guest Dr. Robert Wagner, Director and Chief Medical Officer of Accretive Health tells us more about this program.

Host: Larry Kaskel, MD

Guest: Daniel P. Petrylak, MD

Dr. Larry Kaskel speaks to our guest, Dr. Daniel Petrylak about the current and future bio markers for prostate cancer. What drugs now in clinical trials look promising? How can we expedite drugs from trials to translation? These are just a few interesting questions Dr. Petrylak addresses.

Host: Larry Kaskel, MD

Guest: Daniel P. Petrylak, MD

Why is it so difficult to recommend the best course of treatment for your prostate cancer patients? This segment addresses some of the reasons we have not made as quick progress in developing prostate cancer treatments as we have in some other areas of cancer research. What can we do to advance treatment options for prostate cancer more quickly? Join host, Dr. Larry Kaskel talking with Dr. Daniel Petrylak.

Host: Susan Dolan, RN, JD

Guest: David Feldman, PhD

Dr. David Feldman is assistant professor of counseling psychology at Santa Clara University. Hear Dr. Feldman as he discusses his research and clinical practice involving the role of hope in psychotherapy.